Trial Profile
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Busulfan; Dexamethasone; Enoxaparin sodium; Gemcitabine; Glutamine; Melphalan; Palifermin; Pyridoxine; Rituximab; Vorinostat
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 19 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 22 May 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2016 Planned primary completion date changed from 1 Aug 2021 to 1 Jun 2021.